Tag Archives: patient’s

Crohn’s disease patients have specific IgG antibodies to human bacterial flagellins

Last year, Charles O. Elson, M.D., demonstrated a potential preventive treatment for Crohn’s disease, a form of inflammatory bowel disease. He used a mouse model that included immune-reactive T cells from patients with Crohn’s disease in a flagellin peptide-specific immunotherapy. This study provided proof-of-principle that a flagellin-directed immunotherapy might provide similar benefits in patients. Now… Read More »

Spending on Medicines In and Post-COVID Say a Lot About Patients and Larger Healthcare Trends – an IQVIA Update

Spending on medicines, globally, will rebound this year and rise above pre-pandemic levels through 2025. Between 2021 and 2025, the annual growth global growth rate for prescription drugs spending is expected to range from 3% to 6%, a $ 1.6 trillion bill for the worlds’s total Rx medicines market. That relatively low single-digit growth rate… Read More »

FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status

PRINCETON, N.J.–(BUSINESS WIRE)– April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma, Regardless… Read More »

‘There Was Nothing Anybody Could Do for These Patients.’ Now There Is.

Sonia Sein, outside her Bronx home, had irreparable damage to her trachea. She received a new trachea in January and is believed to be the first patient in the world to undergo a successful direct transplant of a donor trachea.Credit…Sarah Blesener for The New York Times SectionsSkip to contentSkip to site index ‘There Was Nothing… Read More »